Amgen reported a 20% increase in total revenues to $8.4 billion for the second quarter of 2024. Product sales also grew by 20%, driven by a 26% increase in volume. GAAP EPS decreased by 46% to $1.38, while non-GAAP EPS decreased slightly by 1% to $4.97.
Total revenues increased by 20% to $8.4 billion compared to Q2 2023.
Product sales grew by 20%, driven by a 26% increase in volume.
GAAP EPS decreased by 46% to $1.38, driven by higher operating expenses.
Non-GAAP EPS decreased slightly by 1% to $4.97, impacted by higher operating expenses and interest expense.
Amgen provided guidance for the full year 2024, with total revenues expected to be in the range of $32.8 billion to $33.8 billion. GAAP EPS is projected to be between $6.57 and $7.62, and non-GAAP EPS is expected to be in the range of $19.10 to $20.10.
Visualization of income flow from segment revenue to net income